Comprehensive Evaluation of Deubiquitinating Enzymes in Colorectal Cancer: Mechanistic Insights and Potential Therapeutic Approaches
-
By
-
Ting Wang
-
Pingying Li
-
Shuo Xu
-
Guocai Xu
-
April 23, 2026
-
Clinical Scorecard: Comprehensive Evaluation of Deubiquitinating Enzymes in Colorectal Cancer: Mechanistic Insights and Potential Therapeutic Approaches
At a Glance
| Category | Detail |
|---|
| Condition | Colorectal Cancer (CRC) |
| Key Mechanisms | Deubiquitinating enzymes (DUBs) regulate protein stability, DNA damage response, immune evasion, and treatment resistance. |
| Target Population | Patients with colorectal cancer, particularly those with advanced disease and distant metastases. |
| Care Setting | Oncology, specifically in the context of CRC treatment and research. |
Key Highlights
- DUBs play a critical role in CRC progression and treatment resistance.
- DUB-targeting strategies include traditional inhibitors and innovative approaches like PROTACs and DUBTACs.
- DUBs are involved in key pathways such as Wnt/β-catenin and DNA damage repair.
Guideline-Based Recommendations
Diagnosis
- Further elucidation of molecular mechanisms underlying CRC development is essential.
Management
- Targeting DUBs may provide new therapeutic avenues for precision therapy in CRC.
Monitoring & Follow-up
- Assess the expression and function of DUBs as potential biomarkers for CRC progression.
Risks
- Dysfunction of DUBs may contribute to tumor proliferation, invasion, and treatment resistance.
Patient & Prescribing Data
Patients with advanced colorectal cancer.
Innovative DUB-targeting therapies may reverse multidrug resistance.
Clinical Best Practices
- Focus on DUBs that occupy intersections of multiple key phenotypic axes in CRC.
- Establish correspondence between core functional nodes and their translational significance.
References
